세계의 당뇨병 망막증 시장 : 시장 규모, 점유율, 동향 분석(유형별, 관리법별, 지역별), 부문별 예측(2025-2030년)

Diabetic Retinopathy Market Growth & Trends:

The global diabetic retinopathy market is anticipated to reach USD 13.77 billion by 2030 and expand at a CAGR of 6.4% during the forecast period, according to a new report by Grand View Research, Inc. Rising incidence of diabetes in multiple regions and growing awareness regarding the significance of efficient management and effective treatment of Diabetic Retinopathy (DR) are key market drivers. If not treated in time, DR may result in severe vision impairment or even blindness. Improved healthcare infrastructure and increasing accessibility to modern treatments are expected to fuel market growth.

The significant increase in the number of individuals diagnosed with diabetes across multiple regions contributes to growth of this market. Rising awareness regarding the importance of early detection and effective management of blood glucose levels, which reduces the chances of DR, also fuels the market growth. Furthermore, the alarming statistics related to the increasing cases of diabetes-related blindness also increase are expected to support growth of this market.

A report from the American Diabetes Association states that people with diabetes are at risk of developing eye diseases, such as glaucoma, cataracts, and macular edema. DR is considered one of the main reasons for blindness in the U.S. According to the U.S. Centers for Disease Control and Prevention, nearly 38.4 million individuals have diabetes in the U.S.

Diabetic Retinopathy Market Report Highlights:

• Non-proliferative diabetic retinopathy dominated the market with more than 70.0% share in 2024 owing increasing awareness regarding importance of early detection and timely treatment.
• Laser surgery is expected to grow at the fastest CAGR over the forecast period.
• The anti-VEGF management segment held the largest market share of 92.3% in 2024.
• The rise in healthcare investments and advancements in technology contribute to market growth.
• North America dominated the global market owing to increasing awareness, sophisticated healthcare infrastructure, and high market penetration of anti-VEGF drugs.
• In September 2024, India's national regulatory authority approved an ophthalmic AI software, Remidio Medios DR AI, which facilitates the automatic detection of referable DRs.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Management
  • 1.2.3. Regional Scope
  • 1.2.4. Estimates and Forecasts Timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
  • 1.4.5. Details of Primary Research
• 1.5. Information or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Type Outlook
  • 2.2.2. Management Outlook
  • 2.2.3. Regional Outlook
• 2.3. Competitive Insights

Chapter 3. Diabetic Retinopathy Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Diabetic Retinopathy Market Analysis tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrant
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political Landscape
    • 3.3.2.2. Technological Landscape
    • 3.3.2.3. Economic Landscape

Chapter 4. Diabetic Retinopathy Market: Type Estimates & Trend Analysis

• 4.1. Type Segment Dashboard
• 4.2. Diabetic Retinopathy Market: Type Movement Analysis
• 4.3. Global Diabetic Retinopathy Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
• 4.4. Proliferative Diabetic Retinopathy
  • 4.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 4.5. Non-Proliferative Diabetic Retinopathy
  • 4.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 5. Diabetic Retinopathy Market: Management Estimates & Trend Analysis

• 5.1. Management Segment Dashboard
• 5.2. Diabetic Retinopathy Market: Management Movement Analysis
• 5.3. Global Diabetic Retinopathy Market Size & Trend Analysis, by Management, 2018 to 2030 (USD Million)
• 5.4. Anti-VEGF
  • 5.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 5.5. Intraocular Steroid Injection
  • 5.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 5.6. Laser Surgery
  • 5.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 5.7. Vitrectomy
  • 5.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 6. Diabetic Retinopathy Market: Regional Estimates & Trend Analysis

• 6.1. Regional Market Dashboard
• 6.2. Regional Market Share Analysis, 2024 & 2030
• 6.3. Continuous Bioprocessing Market By Region: Key Takeaways
• 6.4. North America
  • 6.4.1. U.S.
    • 6.4.1.1. Key Country Dynamics
    • 6.4.1.2. Regulatory Framework/ Reimbursement Structure
    • 6.4.1.3. Competitive Scenario
    • 6.4.1.4. U.S. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.4.2. Canada
    • 6.4.2.1. Key Country Dynamics
    • 6.4.2.2. Regulatory Framework/ Reimbursement Structure
    • 6.4.2.3. Competitive Scenario
    • 6.4.2.4. Canada Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.4.3. Mexico
    • 6.4.3.1. Key Country Dynamics
    • 6.4.3.2. Regulatory Framework/ Reimbursement Structure
    • 6.4.3.3. Competitive Scenario
    • 6.4.3.4. Canada Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 6.5. Europe
  • 6.5.1. UK
    • 6.5.1.1. Key Country Dynamics
    • 6.5.1.2. Regulatory Framework/ Reimbursement Structure
    • 6.5.1.3. Competitive Scenario
    • 6.5.1.4. UK Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.5.2. Germany
    • 6.5.2.1. Key Country Dynamics
    • 6.5.2.2. Regulatory Framework/ Reimbursement Structure
    • 6.5.2.3. Competitive Scenario
    • 6.5.2.4. Germany Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.5.3. France
    • 6.5.3.1. Key Country Dynamics
    • 6.5.3.2. Regulatory Framework/ Reimbursement Structure
    • 6.5.3.3. Competitive Scenario
    • 6.5.3.4. France Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.5.4. Italy
    • 6.5.4.1. Key Country Dynamics
    • 6.5.4.2. Regulatory Framework/ Reimbursement Structure
    • 6.5.4.3. Competitive Scenario
    • 6.5.4.4. Italy Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.5.5. Spain
    • 6.5.5.1. Key Country Dynamics
    • 6.5.5.2. Regulatory Framework/ Reimbursement Structure
    • 6.5.5.3. Competitive Scenario
    • 6.5.5.4. Spain Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.5.6. Denmark
    • 6.5.6.1. Key Country Dynamics
    • 6.5.6.2. Regulatory Framework/ Reimbursement Structure
    • 6.5.6.3. Competitive Scenario
    • 6.5.6.4. Denmark Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.5.7. Sweden
    • 6.5.7.1. Key Country Dynamics
    • 6.5.7.2. Regulatory Framework/ Reimbursement Structure
    • 6.5.7.3. Competitive Scenario
    • 6.5.7.4. Sweden Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.5.8. Norway
    • 6.5.8.1. Key Country Dynamics
    • 6.5.8.2. Regulatory Framework/ Reimbursement Structure
    • 6.5.8.3. Competitive Scenario
    • 6.5.8.4. Norway Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 6.6. Asia Pacific
  • 6.6.1. Japan
    • 6.6.1.1. Key Country Dynamics
    • 6.6.1.2. Regulatory Framework/ Reimbursement Structure
    • 6.6.1.3. Competitive Scenario
    • 6.6.1.4. Japan Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.6.2. China
    • 6.6.2.1. Key Country Dynamics
    • 6.6.2.2. Regulatory Framework/ Reimbursement Structure
    • 6.6.2.3. Competitive Scenario
    • 6.6.2.4. China Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.6.3. India
    • 6.6.3.1. Key Country Dynamics
    • 6.6.3.2. Regulatory Framework/ Reimbursement Structure
    • 6.6.3.3. Competitive Scenario
    • 6.6.3.4. India Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.6.4. South Korea
    • 6.6.4.1. Key Country Dynamics
    • 6.6.4.2. Regulatory Framework/ Reimbursement Structure
    • 6.6.4.3. Competitive Scenario
    • 6.6.4.4. South Korea Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.6.5. Thailand
    • 6.6.5.1. Key Country Dynamics
    • 6.6.5.2. Regulatory Framework/ Reimbursement Structure
    • 6.6.5.3. Competitive Scenario
    • 6.6.5.4. Thailand Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.6.6. Australia
    • 6.6.6.1. Key Country Dynamics
    • 6.6.6.2. Regulatory Framework/ Reimbursement Structure
    • 6.6.6.3. Competitive Scenario
    • 6.6.6.4. Australia Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 6.7. Latin America
  • 6.7.1. Brazil
    • 6.7.1.1. Key Country Dynamics
    • 6.7.1.2. Regulatory Framework/ Reimbursement Structure
    • 6.7.1.3. Competitive Scenario
    • 6.7.1.4. Brazil Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.7.2. Argentina
    • 6.7.2.1. Key Country Dynamics
    • 6.7.2.2. Regulatory Framework/ Reimbursement Structure
    • 6.7.2.3. Competitive Scenario
    • 6.7.2.4. Argentina Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 6.8. MEA
  • 6.8.1. South Africa
    • 6.8.1.1. Key Country Dynamics
    • 6.8.1.2. Regulatory Framework/ Reimbursement Structure
    • 6.8.1.3. Competitive Scenario
    • 6.8.1.4. South Africa Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.8.2. Saudi Arabia
    • 6.8.2.1. Key Country Dynamics
    • 6.8.2.2. Regulatory Framework/ Reimbursement Structure
    • 6.8.2.3. Competitive Scenario
    • 6.8.2.4. Saudi Arabia Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.8.3. UAE
    • 6.8.3.1. Key Country Dynamics
    • 6.8.3.2. Regulatory Framework/ Reimbursement Structure
    • 6.8.3.3. Competitive Scenario
    • 6.8.3.4. UAE Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.8.4. Kuwait
    • 6.8.4.1. Key Country Dynamics
    • 6.8.4.2. Regulatory Framework/ Reimbursement Structure
    • 6.8.4.3. Competitive Scenario
    • 6.8.4.4. Kuwait Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company/Competition Categorization
• 7.3. Vendor Landscape
  • 7.3.1. Key Company Heat Map Analysis, 2024
• 7.4. Company Profiles
  • 7.4.1. Bayer AG
    • 7.4.1.1. Company Overview
    • 7.4.1.2. Financial Performance
    • 7.4.1.3. Product Benchmarking
    • 7.4.1.4. Strategic Initiatives
  • 7.4.2. AbbVie Inc.
    • 7.4.2.1. Company Overview
    • 7.4.2.2. Financial Performance
    • 7.4.2.3. Product Benchmarking
    • 7.4.2.4. Strategic Initiatives
  • 7.4.3. Novartis AG
    • 7.4.3.1. Company Overview
    • 7.4.3.2. Financial Performance
    • 7.4.3.3. Product Benchmarking
    • 7.4.3.4. Strategic Initiatives
  • 7.4.4. Oxurion NV.
    • 7.4.4.1. Company Overview
    • 7.4.4.2. Financial Performance
    • 7.4.4.3. Product Benchmarking
    • 7.4.4.4. Strategic Initiatives
  • 7.4.5. Sirnaomics, Inc.
    • 7.4.5.1. Company Overview
    • 7.4.5.2. Financial Performance
    • 7.4.5.3. Product Benchmarking
    • 7.4.5.4. Strategic Initiatives
  • 7.4.6. Alimera Sciences
    • 7.4.6.1. Company Overview
    • 7.4.6.2. Financial Performance
    • 7.4.6.3. Product Benchmarking
    • 7.4.6.4. Strategic Initiatives
  • 7.4.7. Ampio Pharmaceuticals Inc.
    • 7.4.7.1. Company Overview
    • 7.4.7.2. Financial Performance
    • 7.4.7.3. Product Benchmarking
    • 7.4.7.4. Strategic Initiatives
  • 7.4.8. BCN Peptides
    • 7.4.8.1. Company Overview
    • 7.4.8.2. Financial Performance
    • 7.4.8.3. Product Benchmarking
    • 7.4.8.4. Strategic Initiatives
  • 7.4.9. Kowa Company, Ltd.
    • 7.4.9.1. Company Overview
    • 7.4.9.2. Financial Performance
    • 7.4.9.3. Product Benchmarking
    • 7.4.9.4. Strategic Initiatives
  • 7.4.10. Genentech, Inc.
    • 7.4.10.1. Company Overview
    • 7.4.10.2. Financial Performance
    • 7.4.10.3. Product Benchmarking
    • 7.4.10.4. Strategic Initiatives